General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 341: Which of the following statements regarding enzyme inhibition is true?

A. Sulfonamides inhibit dihydrofolate reductase irreversibly.
B. Ethanol inhibits alcohol dehydrogenase when used in methanol poisoning.
C. Acetylcholinesterase inhibition by malathion can be reversed by increasing the levels of acetylcholine.
D. Fluoroacetate competitively inhibits aconitase. (Correct Answer)

Explanation: ### Explanation **Correct Option: D. Fluoroacetate competitively inhibits aconitase.** Fluoroacetate is a classic example of **"Lethal Synthesis."** It is not toxic itself but is converted in the body to **fluorocitrate**. Fluorocitrate then acts as a competitive inhibitor of the enzyme **aconitase** in the Krebs cycle. This blockade halts cellular respiration, leading to toxicity. **Analysis of Incorrect Options:** * **A. Sulfonamides:** These are structural analogs of PABA and **competitively** (not irreversibly) inhibit **Dihydropteroate synthase**. It is *Trimethoprim* and *Methotrexate* that inhibit Dihydrofolate reductase. * **B. Ethanol in Methanol Poisoning:** Ethanol acts as a **competitive inhibitor** of Alcohol Dehydrogenase (ADH). By having a higher affinity for ADH, ethanol prevents the conversion of methanol into its toxic metabolites (formaldehyde and formic acid). * **C. Malathion:** This is an organophosphate that inhibits Acetylcholinesterase **irreversibly** (covalent bonding). Unlike competitive inhibition, irreversible inhibition **cannot** be reversed by simply increasing the substrate (Acetylcholine) concentration. **NEET-PG High-Yield Pearls:** 1. **Competitive Inhibition:** $V_{max}$ remains unchanged, $K_m$ increases. It can be overcome by increasing substrate concentration (e.g., Neostigmine for Curare poisoning). 2. **Non-competitive Inhibition:** $V_{max}$ decreases, $K_m$ remains unchanged (e.g., Acetazolamide, Digoxin). 3. **Suicide Inhibition:** A form of irreversible inhibition where the enzyme converts an inactive substrate into a reactive inhibitor that binds permanently (e.g., Allopurinol to Alloxanthine, Aspirin, 5-Fluorouracil).

Question 342: Therapeutic Drug Monitoring (TDM) involves measurement of plasma concentrations of drugs to determine if the drug levels are within the therapeutic range. For TDM to be clinically useful, which of the following criteria should be fulfilled?

A. There should be a good relationship between plasma concentration and drug dosage.
B. The relationship between plasma drug concentration and therapeutic response and/or toxicity should be poor.
C. When pharmacodynamic tolerance is suspected.
D. When the clinical response cannot be easily monitored. (Correct Answer)

Explanation: Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring drug concentrations in plasma to optimize a patient’s drug regimen. **Why Option D is Correct:** The primary utility of TDM arises when the **clinical effect of a drug cannot be easily measured** or observed. For example, with drugs like Phenytoin (antiepileptic) or Lithium (mood stabilizer), it is difficult to quantify the immediate clinical response to prevent a future seizure or manic episode [1]. In contrast, drugs like antihypertensives (monitored via blood pressure) or anticoagulants (monitored via INR/PT) do not require TDM because their clinical effect is easily quantifiable. **Analysis of Incorrect Options:** * **Option A:** TDM is actually most useful when there is a **poor/unpredictable relationship** between drug dosage and plasma concentration (e.g., due to individual variations in metabolism or malabsorption) [1]. If the relationship were predictable, measuring plasma levels would be unnecessary. * **Option B:** For TDM to be valid, there must be a **strong correlation** between the plasma concentration and the therapeutic or toxic effect [1]. If this relationship is poor, the plasma level provides no useful information about the patient's clinical state. * **Option C:** In cases of **pharmacodynamic tolerance**, the body’s receptors become less sensitive to the drug. In this scenario, plasma levels may appear "normal" or "therapeutic," but the patient fails to respond, making TDM misleading rather than helpful. **High-Yield NEET-PG Pearls:** * **Criteria for TDM:** Narrow therapeutic index [1], unpredictable pharmacokinetics [1], lack of easily measurable clinical markers, and suspected non-compliance or toxicity. * **Drugs requiring TDM:** Lithium, Digoxin [1], Aminoglycosides (Gentamicin), Phenytoin [1], Theophylline [1], Cyclosporine [1], and Tricyclic Antidepressants. * **Drugs NOT requiring TDM:** Those with a wide therapeutic window or those with easily measurable effects (e.g., ACE inhibitors, Warfarin, Oral Hypoglycemics).

Question 343: Pharmacoepidemiology is associated with which phase of clinical trials?

A. Phase 0
B. Phase II
C. Phase IV
D. Phase V (Correct Answer)

Explanation: **Explanation:** **1. Why Phase V is the Correct Answer:** While Phase IV (Post-Marketing Surveillance) involves monitoring the safety and efficacy of a drug in the general population, **Phase V** specifically refers to **Pharmacoepidemiology** and translational research. It focuses on the study of drug effects, risks, and benefits in large populations over long periods using epidemiological methods [1]. It evaluates how a drug performs in "real-world" clinical practice compared to the controlled environment of clinical trials, often influencing public health policies and guidelines. **2. Why Other Options are Incorrect:** * **Phase 0 (Microdosing):** These are human microdosing studies conducted in a small number of subjects (10–15) to study pharmacokinetics (PK) and pharmacodynamics (PD) before Phase I. * **Phase II (Therapeutic Exploratory):** This phase tests the drug on a small group of patients (100–300) to determine efficacy and establish the therapeutic dose range [1]. * **Phase IV (Post-Marketing Surveillance):** This phase begins after the drug is marketed to detect rare adverse effects. While closely related, Pharmacoepidemiology is technically categorized as Phase V in modern clinical research frameworks. **3. High-Yield Clinical Pearls for NEET-PG:** * **Phase I:** Safety and Tolerability (usually in healthy volunteers, except for anti-cancer drugs) [2]. * **Phase III:** Therapeutic Confirmatory (large-scale RCTs; the basis for New Drug Application/NDA). * **Phase IV:** Detects "Rare Adverse Events" (e.g., Phocomelia, which led to the strengthening of these trials). * **Phase V:** Focuses on the "Effectiveness" in the community and long-term population impact. * **N-of-1 Trials:** A trial where a single patient is the sole subject, often used to determine the best treatment for that specific individual.

Question 344: Basiliximab is a monoclonal antibody against which receptor?

A. IL-2 receptor (Correct Answer)
B. CD20
C. INF-α
D. IL-6

Explanation: **Explanation:** **Basiliximab** is a chimeric monoclonal antibody (mouse-human) that acts as a potent immunosuppressant. Its mechanism of action involves binding specifically to the **α-subunit (CD25)** of the **Interleukin-2 (IL-2) receptor** expressed on the surface of activated T-lymphocytes. By competitively inhibiting IL-2 from binding to its receptor, it prevents T-cell proliferation and activation, which are critical steps in the immune response against transplanted organs. **Analysis of Options:** * **Option A (IL-2 receptor):** Correct. Basiliximab (and Daclizumab) are IL-2 receptor antagonists used primarily as "induction therapy" in renal transplantation to prevent acute organ rejection. * **Option B (CD20):** Incorrect. **Rituximab** is the monoclonal antibody directed against CD20, primarily used in B-cell non-Hodgkin lymphomas and Rheumatoid Arthritis. * **Option C (INF-α):** Incorrect. While there are no major monoclonal antibodies targeting INF-α used in standard transplant protocols, drugs like Sifalimumab have been studied for SLE. * **Option D (IL-6):** Incorrect. **Tocilizumab** and Sarilumab are the monoclonal antibodies that target IL-6 receptors, used in Rheumatoid Arthritis and Cytokine Release Syndrome (CRS). **High-Yield Clinical Pearls for NEET-PG:** * **Indication:** Prophylaxis of acute organ rejection in renal transplants (Induction therapy). * **Mnemonic:** "Basiliximab binds the **B**-chain (actually the alpha chain/CD25) to block the **B**-last (T-cell blast/proliferation)." * **Side Effects:** Generally well-tolerated; unlike older agents, it does not typically cause cytokine release syndrome. * **Comparison:** Unlike Muromonab-CD3 (which depletes T-cells), Basiliximab only inhibits *activated* T-cells.

Question 345: Which of the following statements about phase IV clinical trials is true?

A. It is conducted for pediatric drugs
B. It is conducted for rare drugs
C. It is post-marketing surveillance of drugs (Correct Answer)
D. It is also called human pharmacology and safety studies

Explanation: **Explanation:** **Phase IV Clinical Trials** are also known as **Post-Marketing Surveillance (PMS)**. These trials begin after a drug has been approved by regulatory authorities (like the FDA or CDSCO) and is available on the market for the general population. 1. **Why Option C is Correct:** Unlike Phase I-III trials, which involve a limited number of selected participants under controlled conditions, Phase IV monitors the drug's performance in the "real world." Its primary goal is to detect **rare adverse effects**, long-term risks, and benefits that were not evident during the shorter, smaller pre-approval trials. 2. **Why Other Options are Incorrect:** * **Option A:** Drugs for pediatric use undergo specific pediatric clinical trials (often Phase IIIb), but Phase IV is not defined by the age group; it is defined by the timing (post-approval). * **Option B:** Drugs for rare diseases are called **Orphan Drugs**. While they undergo Phase IV like any other drug, Phase IV itself is not a study specifically "for rare drugs." * **Option C:** "Human pharmacology and safety studies" refers to **Phase I** clinical trials, where the drug is first tested in a small group of healthy volunteers to determine safety and pharmacokinetics. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0:** Microdosing studies (sub-therapeutic doses) used to determine PK parameters. * **Phase I:** Safety and Tolerability (Healthy volunteers, except for oncology drugs). * **Phase II:** Therapeutic **Exploration** (Small group of patients; determines dose-range). * **Phase III:** Therapeutic **Confirmation** (Large multicentric RCTs; establishes efficacy against placebo or gold standard). * **Phase IV:** Post-marketing surveillance; identifies **idiosyncratic reactions** and rare side effects (e.g., the withdrawal of Rofecoxib due to cardiovascular risks).

Question 346: The rate of elimination with first-order kinetics is proportional to which of the following?

A. Plasma concentration (Correct Answer)
B. Loading dose
C. Maintenance dose
D. Renal plasma flow

Explanation: ### Explanation In **First-Order Kinetics** (Linear Kinetics), a constant **fraction** of the drug is eliminated per unit of time. This means the actual amount of drug removed is directly proportional to the amount of drug present in the body. **1. Why Option A is Correct:** The mathematical equation for the rate of elimination is: **Rate of elimination = CL × C** *(Where CL = Clearance and C = Plasma Concentration)* Since clearance remains constant in first-order kinetics, the rate of elimination increases linearly as the plasma concentration increases. Most drugs follow this pattern at therapeutic doses. **2. Why Other Options are Incorrect:** * **B. Loading Dose:** This is the initial dose given to achieve target plasma concentration rapidly. It determines the starting concentration but does not dictate the ongoing *rate* of elimination. * **C. Maintenance Dose:** This is the dose required to maintain a steady state. While it is calculated based on the clearance, the rate of elimination itself is driven by the concentration achieved, not the dose administered. * **D. Renal Plasma Flow:** While renal flow affects the clearance of drugs primarily excreted by the kidneys, it is a physiological parameter of the organ, not the kinetic principle defining the rate of elimination for all drugs. ### High-Yield Clinical Pearls for NEET-PG: * **First-Order Kinetics:** Constant **fraction** eliminated; Half-life ($t_{1/2}$) is **constant**; most drugs follow this. * **Zero-Order Kinetics:** Constant **amount** eliminated; Half-life is **variable** (proportional to concentration). * **Mnemonic for Zero-Order Drugs:** **"WATT"** – **W**arfarin (at high doses), **A**lcohol/Aspirin, **T**heophylline, **T**olbutamide/Pheny**t**oin. * **Steady State:** Reached after **4–5 half-lives**, regardless of the dose or frequency of administration.

Question 347: Which of the following properties of a drug will enable it to be used in low concentration?

A. High affinity (Correct Answer)
B. High specificity
C. Low specificity
D. High stability

Explanation: **Explanation:** The correct answer is **High affinity**. **1. Why High Affinity is Correct:** Affinity refers to the chemical force that causes a drug to bind to its receptor. It is the measure of how tightly a drug binds to its target. In pharmacological terms, affinity is inversely proportional to the **Dissociation Constant ($K_d$)**. A drug with high affinity requires a very low concentration to occupy 50% of the available receptors. Therefore, drugs with high affinity can achieve their desired pharmacological effect even at low doses or concentrations. **2. Why Other Options are Incorrect:** * **High Specificity:** Specificity refers to the ability of a drug to act on a particular receptor type or tissue. While highly specific drugs have fewer side effects, specificity does not dictate the *amount* or *concentration* of the drug needed to trigger a response. * **Low Specificity:** This implies the drug binds to multiple receptor types (promiscuity), which usually leads to a higher incidence of adverse effects, but it does not determine the potency or concentration required for action. * **High Stability:** This relates to the drug's resistance to degradation (metabolism) and its shelf-life. While stability affects the duration of action and storage, it does not determine the concentration needed to initiate a receptor-mediated response. **3. NEET-PG High-Yield Pearls:** * **Potency vs. Efficacy:** Affinity is a major determinant of **Potency** (the amount of drug needed for an effect). **Efficacy** (Intrinsic Activity) is the ability of the drug to activate the receptor once bound. * **$K_d$ Relationship:** A lower $K_d$ value signifies higher affinity. * **Agonists vs. Antagonists:** Both agonists and antagonists possess affinity, but only agonists possess intrinsic activity (efficacy).

Question 348: Which of the following is not an alkaloid?

A. Morphine
B. Neostigmine (Correct Answer)
C. Emetine
D. Atropine

Explanation: **Explanation:** The core concept behind this question lies in distinguishing between **natural alkaloids** and **synthetic/semi-synthetic compounds**. **Why Neostigmine is the correct answer:** Alkaloids are naturally occurring organic nitrogenous compounds, mostly derived from plants, that produce physiological actions. **Neostigmine** is a **synthetic** quaternary ammonium compound. While it was structurally modeled after Physostigmine (a natural alkaloid from the Calabar bean), Neostigmine itself does not occur in nature. It is designed to be polar, meaning it does not cross the blood-brain barrier, unlike its natural counterpart. **Analysis of incorrect options:** * **Morphine:** A classic natural alkaloid derived from the opium poppy (*Papaver somniferum*). It is the prototype opioid analgesic. * **Emetine:** A natural alkaloid derived from the ipecacuanha root (*Cephaelis ipecacuanha*). It was historically used as an emetic and in the treatment of amoebiasis. * **Atropine:** A natural belladonna alkaloid extracted from plants like *Atropa belladonna* (Deadly Nightshade). It acts as a competitive antagonist at muscarinic receptors. **High-Yield NEET-PG Pearls:** * **Physostigmine vs. Neostigmine:** Physostigmine is a tertiary amine (natural alkaloid) that **crosses** the BBB (used for Atropine poisoning). Neostigmine is a quaternary ammonium (synthetic) that **does not cross** the BBB (used for Myasthenia Gravis and reversing neuromuscular blockade). * **Other common alkaloids:** Quinine, Reserpine, Vincristine, and Nicotine. * **Identification Test:** Alkaloids typically give a positive result with **Mayer’s reagent** (creamy precipitate) or **Dragendorff’s reagent** (orange-red precipitate).

Question 349: A 500-mg dose of a drug has therapeutic efficacy for 6 hours. If the half-life of the drug is 8 hours, for how long would a 1-gm dose be effective?

A. 12 hours
B. 14 hours (Correct Answer)
C. 16 hours
D. 24 hours

Explanation: ### Explanation This question tests the understanding of **Drug Half-life ($t_{1/2}$)** and its relationship with the duration of action. **1. Why Option B is Correct:** The duration of action of a drug is determined by the time it takes for the plasma concentration to fall below the **Minimum Effective Concentration (MEC)**. * **Initial Scenario:** A 500 mg dose is effective for 6 hours. This means that after 6 hours, the amount of drug remaining in the body is the MEC. * **Second Scenario:** The dose is doubled to 1000 mg (1 gm). * According to the principle of pharmacokinetics, **doubling the dose of a drug increases its duration of action by exactly one half-life.** * Since the drug has a half-life of 8 hours, it will take 8 hours for the 1000 mg dose to reduce to 500 mg. * Once it reaches 500 mg, we already know from the first scenario that it takes another 6 hours to fall below the MEC. * **Total Duration** = 8 hours (to reach 500 mg) + 6 hours (to fall below MEC) = **14 hours.** **2. Why Other Options are Incorrect:** * **Option A (12 hours):** This assumes a linear relationship between dose and duration, which is incorrect. Drug elimination follows exponential (first-order) kinetics, not linear. * **Option C (16 hours):** This incorrectly assumes that doubling the dose doubles the duration of action (6 x 2 = 12) or adds a full half-life to the original duration without accounting for the starting point. * **Option D (24 hours):** This is a random calculation error, likely confusing three half-lives with the duration of action. **3. NEET-PG Clinical Pearls:** * **First-Order Kinetics:** Most drugs follow this, where a constant *fraction* of the drug is eliminated per unit time. * **Rule of Thumb:** If the dose is increased by a factor of $2^n$, the duration of action increases by $n \times t_{1/2}$. Here, the dose increased by $2^1$, so duration increased by $1 \times t_{1/2}$. * **Steady State:** It takes 4–5 half-lives to reach a steady-state concentration during constant dosing.

Question 350: What is a specific side effect of thalidomide?

A. Lymphopenia
B. Lymphocytosis
C. Phocomelia (Correct Answer)
D. Optic neuritis

Explanation: **Explanation:** **Thalidomide** is a classic example of a potent **teratogen**. The correct answer is **Phocomelia**, a condition characterized by "seal-like limbs" where the long bones of the extremities are absent or significantly underdeveloped, causing the hands or feet to be attached directly to the trunk. 1. **Mechanism of Phocomelia:** Thalidomide was originally used in the 1950s as a sedative and anti-emetic for morning sickness. It was later discovered that exposure during the first trimester (specifically days 24–36 of gestation) inhibits angiogenesis and interferes with the protein **Cereblon**, which is essential for limb bud development. This led to the "Thalidomide Tragedy," resulting in thousands of babies born with phocomelia. 2. **Analysis of Incorrect Options:** * **Lymphopenia/Lymphocytosis:** Thalidomide has immunomodulatory effects (inhibits TNF-α), but it is not specifically known for causing significant fluctuations in lymphocyte counts as a primary diagnostic side effect. * **Optic Neuritis:** This is a classic side effect of **Ethambutol** (anti-tubercular drug), not thalidomide. Thalidomide is more commonly associated with peripheral neuropathy. **High-Yield Clinical Pearls for NEET-PG:** * **Current Uses:** Despite its teratogenicity, thalidomide is now a first-line treatment for **Multiple Myeloma** and **Erythema Nodosum Leprosum (ENL)**. * **Mechanism:** It acts by inhibiting **TNF-α** and angiogenesis. * **Regulatory Fact:** The thalidomide disaster led to the strengthening of the FDA and more stringent drug testing regulations (Kefauver-Harris Amendment). * **Contraception:** Due to its high teratogenic risk, it is strictly contraindicated in pregnancy (Category X) and requires the "STEPS" program for risk management.

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free